Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.46 |
| ▸ | THRA | P10827 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678199 | 0.84 | CETP (0.42) | — | |
| SCHEMBL11733830 | 0.82 | CETP (0.40) | — | |
| SCHEMBL6675434 | 0.82 | CETP (0.40) | — | |
| SCHEMBL20427410 | 0.81 | RARB (0.52) | RARBMEN1KMT2AALDH1A1RARA | |
| SCHEMBL23696090 | 0.77 | RARB (0.51) | RARBMEN1KMT2AALDH1A1RARA | |
| SCHEMBL8605152 | 0.77 | RARB (0.48) | RARBMEN1KMT2AALDH1A1RARA | |
| SCHEMBL21439988 | 0.76 | L3MBTL1 (0.41) | THRATHRB | |
| SCHEMBL3316315 | 0.75 | RXRA (0.50) | KMT2AALDH1A1PLA2G4B | |
| SCHEMBL23962128 | 0.74 | ALDH1A1 (0.48) | RARBALDH1A1MAPT | |
| SCHEMBL6322340 | 0.74 | PLA2G4B (0.53) | RARBMEN1KMT2AALDH1A1RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312942-B2 | Material-fixing substrate and method for producing same, and material-fixing agent used for material-fixing substrate | SONY CORPORATION (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20210401997-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2021-12-30 | — | — | US | disclosed |
| US-20200318076-A1 | MATERIAL-FIXING SUBSTRATE AND METHOD FOR PRODUCING SAME, AND MATERIAL-FIXING AGENT USED FOR MATERIAL-FIXING SUBSTRATE | SONY CORPORATION (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10434111-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190216910-A1 | BIOMATERIALS FOR MODULATING IMMUNE RESPONSES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2019-07-18 | — | — | US | disclosed |
| US-20180117171-A1 | IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216910-A1 | BIOMATERIALS FOR MODULATING IMMUNE RESPONSES | CD47, CD14, TLR3 | RARB 1284/4885MEN1 2598/4885KMT2A 3530/4885 |
| US-20180117171-A1 | IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS | FCGR1A, FCGR3B, FCER2 | RARB 477/4885MEN1 3617/4885KMT2A 2365/4885 |
| US-10434111-B2 | Compositions and methods for modification of biomolecules | PTMS, QPCT, ANPEP | RARB 4715/4885MEN1 2583/4885KMT2A 4132/4885 |
| US-20210401997-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | RARB 4442/4885MEN1 171/4885KMT2A 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.